The SOUL trial showed that oral semaglutide was safe in patients with type 2 diabetes and atherosclerotic cardiovascular disease or chronic kidney disease.
The post Oral Semaglutide Yields Excellent CV Outcomes in High-Risk Type 2 Diabetes first appeared on Physician’s Weekly.
